Cheers for this, I'd be keen to hear your view then on why canaloplasty specifically has proved to be very effective at treating this type of glaucoma? I can find the study later if you like, but they recently presented data from a large data registry at a conference showing something around a 40% (if I remember correctly) reduction in IOP for closed angle glaucoma with iTrack Advance (which, assuming the criteria for success is similar in closed angle as it is to open angle, is very significant). I'd assume blocked access to the Schlemm's canal would also restrict the use of iTrack Advance, but apparently not?
EYE Summary (August 2024): Incredibly Undervalued, page-83
-
- There are more pages in this discussion • 294 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.5¢ | 18.5¢ | $12.62K | 66.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49388 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 63159 | 2 |
View Market Depth
| Last trade - 12.20pm 18/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |